Jubilant Ingrevia's JAEL executes 40% Zettaone agreement

Jubilant Ingrevia Limited said on November 8, 2026 that its wholly owned subsidiary, Jubilant Advanced Electronics Limited, had executed an agreement to acquire a 40% strategic equity stake in Zettaone Technologies India Private Limited, with an option to increase the holding to 51% during FY28.

What agreement did Jubilant Ingrevia execute with Zettaone?

Jubilant Ingrevia said Jubilant Advanced Electronics Limited (JAEL) executed a Share Subscription and Share Purchase Agreement (SSPA) to acquire a 40% strategic equity stake in Zettaone Technologies India Private Limited (Zettaone). The company reported the event to the exchanges on November 8, 2026, with the time of occurrence recorded as 10:51 am Indian Standard Time.

The SSPA execution advances the transaction from Jubilant Ingrevia's October 1, 2026 disclosure that JAEL, rather than the company directly, would undertake the acquisition. The November 8 filing says the key terms and details were already disclosed in that earlier communication, while the new update confirms that the agreement has been executed.

The November 8 announcement does not state the consideration, valuation, closing date or Zettaone financial information. It also does not say that the 40% acquisition has closed, so the reported development is the execution of the SSPA rather than a confirmed completed transfer of shares.

How is Jubilant Ingrevia making the Zettaone investment?

Jubilant Ingrevia is making the investment through JAEL, its wholly owned subsidiary, rather than through a direct purchase by Jubilant Ingrevia. The company had disclosed this transaction route on October 1, 2026, and the November 8 filing confirms that JAEL is the party that executed the SSPA.

This means the disclosed 40% strategic equity stake will sit with JAEL. Jubilant Ingrevia does not describe Zettaone as its subsidiary in the November 8 update, and the initial 40% stake is below the possible 51% holding identified for FY28.

The filing also places the future option with JAEL. Jubilant Ingrevia said JAEL may increase its shareholding to 51% during FY28, subject to the terms and conditions of the SSPA, but it does not disclose any price, operating threshold, approval requirement or other specific condition attached to that option.

Can Jubilant Ingrevia raise its Zettaone stake to 51%?

Jubilant Ingrevia said JAEL has an option to increase its Zettaone holding from 40% to 51% during FY28. The company qualifies the option by stating that it remains subject to the terms and conditions of the SSPA.

A move from 40% to 51% would represent an increase of 11 percentage points. However, the November 8 filing does not say the option has been exercised, does not set a specific date in FY28 for a decision, and does not give the financial terms that would apply to the additional stake.

Jubilant Ingrevia described the potential 51% holding as making the acquisition more important to its overall growth journey. That is management's stated strategic view, rather than a forecast of revenue, profit, capacity or customer additions from either the 40% investment or a possible 51% holding.

Why is Jubilant Ingrevia entering electronics design and manufacturing services?

Jubilant Ingrevia said the acquisition marks its entry into electronics design and manufacturing services (EDMS). The company described EDMS as a rapidly growing sector and said the investment is expected to create a platform to serve customers across semiconductors, aerospace and defense, automotive and other electronics segments.

The company linked the investment to its semiconductor and electronics chemicals vertical. Jubilant Ingrevia said it expects to leverage its manufacturing excellence and customer-centric capabilities in the CDMO space alongside Zettaone's EDMS capabilities to offer customers an integrated value proposition.

The filing does not quantify the EDMS market, identify customer programmes, or provide a timetable for serving the semiconductor, aerospace and defense, automotive or other electronics segments. It also does not specify products, manufacturing capacity or revenue that Zettaone will contribute to the semiconductor and electronics chemicals vertical.

What changed between the October and November disclosures?

The change between the October 1, 2026 and November 8, 2026 disclosures is that JAEL has now executed the SSPA for the 40% Zettaone stake. The October communication, as described in the latest filing, had informed exchanges that the acquisition would be undertaken through JAEL instead of directly by Jubilant Ingrevia.

The November update retains the same initial 40% stake and the same option to reach 51% during FY28. It adds the agreement-execution milestone but does not provide a new purchase price, valuation, completion date, ownership breakdown for other shareholders or financial target for the EDMS platform.

Jubilant Ingrevia presents the transaction as an addition to its existing CDMO capabilities. Its stated mechanism is to combine those capabilities with Zettaone's EDMS capabilities, with the aim of accelerating growth in the semiconductor and electronics chemicals vertical.

Conclusion

The November 8 disclosure confirms that JAEL has executed the SSPA for Jubilant Ingrevia's planned 40% strategic stake in Zettaone. The company says the transaction gives it an EDMS entry point and links Zettaone's capabilities with its CDMO operations and semiconductor and electronics chemicals vertical.

The next disclosed milestone is JAEL's FY28 option to raise its Zettaone holding from 40% to 51%, subject to the SSPA's terms and conditions. Jubilant Ingrevia has not provided a specific FY28 exercise date, the conditions of the option, or financial measures for the investment in this update.